ATP Antagonizes Thrombin-Induced Signal Transduction through 12(S)-HETE and cAMP

Jaione Burzaco1, Manuel Conde1, Luis A. Parada2, José L. Zugaza3,4,5,*, Jean-Paul Dehaye6, Aida Marino1*

1 Department of Biochemistry and Molecular Biology, Faculty of Science and Technology, University of the Basque Country, Bilbao, Spain, 2 Instituto de Patología Experimental, Universidad Nacional de Salta, Salta, Argentina, 3 Department Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of the Basque Country, Bilbao, Spain, 4Achucarro Basque Center for Neuroscience, Bizkaia Science and Technology Park, Zamudio, Spain, 5 Ikerbasque, Basque Foundation for Science, Bilbao, Spain, 6 Biochemistry and Cellular Biology Laboratory, Institute of Pharmacy C.P. 205/3, Université Libre de Bruxelles, Brussels, Belgium

Abstract

In this study we have investigated the role of extracellular ATP on thrombin induced-platelet aggregation (TIPA) in washed human platelets. ATP inhibited TIPA in a dose-dependent manner and this inhibition was abolished by apyrase but not by adenosine deaminase (ADA) and it was reversed by extracellular magnesium. Antagonists of P2Y1 and P2Y12 receptors had no effect on this inhibition suggesting that a P2X receptor controlled ATP-mediated TIPA inhibition. ATP also blocked inositol phosphates (IP1, IP2, IP3) generation and [Ca2+] mobilization induced by thrombin. Thrombin reduced cAMP levels which were restored in the presence of ATP. SQ-22536, an adenylate cyclase (AC) inhibitor, partially reduced the inhibition exerted by ATP on TIPA. 12-lipoxygenase (12-LO) inhibitors, nordihydroguaretic acid (NDGA) and 15(S)-hydroxy-5,8,11,13-eicosatetraenoic acid (15(S)-HETE), strongly prevented ATP-mediated TIPA inhibition. Additionally, ATP inhibited the increase of 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid (12(S)-HETE) induced by thrombin. Pretreatment with both SQ-22536 and NDGA almost completely abolished ATP-mediated TIPA inhibition. Our results describe for the first time that ATP implicates both AC and 12-LO pathways in the inhibition of human platelets aggregation in response to agonists.

Introduction

Activation of human platelets is a key event in the processes of hemostasis and thrombosis. Several agonists including ADP, thrombin, and thromboxane A2 (TXA2) can activate platelets [1]. These agonists affect platelets leading to shape change, aggregation, or promoting that the granule release their content [2]. Thrombin is a serine protease which is activated by extrinsic and intrinsic coagulation cascades at the vascular injury site. It is not only a coagulation enzyme catalysing the conversion of soluble fibrinogen into an insoluble fibrin clot, but also an extremely important agonist for platelet activation [3]. Thrombin primarily mediates cellular effects through protease-activated receptors (PARs). Three of the four PARs known (PAR1, PAR3 and PAR4) are activated by thrombin with PAR1 and PAR4 being present in human platelets. Both receptors are coupled to a Goi,βi subunit [4].

ADP is released during platelet activation, becoming a critical molecule in hemostasis. ADP also cooperates with other molecules, including thrombin, to potentiate many platelet responses [5]. Two different P2 receptors, P2Y1 and P2Y12, involved in the ADP-induced platelet responses have been cloned. The P2Y1 receptor mediates PLC activation via a Goi subunit and subsequently regulates intracellular calcium ([Ca2+]i) mobilization and platelet shape changes [5]. P2Y12 receptor, on the other hand, is coupled to the Gs subunit, which prevents the activation of AC, whereupon the intracellular cAMP concentration decreases. P2Y12 receptor behaves as a negative regulator of platelet activation [6]. The P2Y12-dependent Gs activation also potentiates the release of granule contents [7] and can directly activate the αIIbβ3 integrin via phosphoinositide-3 kinase [8–11].

ADP-induced platelet aggregation requires coactivation of P2Y1 and P2Y12 receptors [12]. Thrombin and thrombin receptor-activating peptides (TRAPs) have been shown to activate both Gs and Gi pathways [13] but unlike ADP, thrombin alone is unable to activate both pathways [14]. Glycoprotein Ibα and ADP act synergistically to amplify the PAR1- but not the PAR4-coupled responses [15]. Thrombin not only requires secreted ADP and P2Y12 activation to stimulate Gs and activate PAR1 via Gsi but also, at high concentrations, it can regulate PAR4 pathway [16]. It has been described that ticagrelor and other cyclopentyltriazolo-pyrimidines (P2Y12 antagonists) selectively block the ADP component in the thrombin response resulting in a potent inhibition of platelet activation whereas they are ineffective for P2Y1 [17].
ATP and ADP are present in platelets at approximately equimolar concentrations [18] and extracellular ATP inhibits ADP-induced platelet activation, since it acts as a competitive antagonist through P2Y1 and P2Y12 receptors [19]. It has been reported that ATP stimulates P2X1 receptor in human platelets and increases the intracellular calcium concentration without generating platelet aggregation [20]. Moreover, studies on transgenic animals showed that P2X receptors play an important role in platelet activation, particularly under conditions of shear stress and thus during arterial thrombosis [21]. Besides, this receptor could be involved in the aggregation of human platelets induced by collagen [22].

ATP and other nucleotides such as, GTP, GDP or GDP-β-S inhibit both thrombin- and ADP-mediated platelet activation [23]. TIPA and the inhibition of the cellular secretion mediated by ATP is accompanied by a decrease in [Ca²⁺]i mobilization, this suggests that an extracellular P2X-like site could be responsible for the effects of these nucleotides [23]. Dragan and Ellis found that thrombin-untreated cells, extracellular ATP, GTP and AMP increased the 12(S)-HETE production. ATP activated 12-LO by an unknown mechanism and increased by 3-fold the 12(S)-HETE formation. A purinergic binding site is proposed to activate this pathway [24].

The aim of this work was to examine the interaction between extracellular ATP and platelets exposed to thrombin. Our results suggest that AC and the 12-LO pathways are implicated in the inhibition of TIPA mediated by ATP. This physiological inhibition of human platelets in response to strong agonists is mediated by a combined action between the P2Y12 receptor and the inhibition of the intracellular levels of 12(S)-HETE.

Materials and Methods

Reagents

Adenosine 3', 5' biphosphate (A₂P₂), fibrinogen, acid citrate dextrose, ADA, ADP, ATP, α,β-methylene ATP, βγ-methylene ATP, benzoyl ATP, 2 methylthio ATP, apyrase, ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), N-[2-hydroxyethyl] piperazine-N'-[2-ethanesulfonic acid] (HEPES), 15(S)-HETE, 3-iso-butyl-1-methylxanthine (IBMX), miltirone, diprydamole, NDGA, protein kinase, 3', 5'-cyclic AMP dependent (PKA), polyethylenimine, sodium nitroprusside (SNP) and thrombin were obtained from Sigma-Aldrich Chemical (St. Louis MO, USA). Fura-2 AM was from Molecular Probes (Eugene OR, USA). Myo-[3H]inositol was from GE Healthcare (Barcelona, Spain). Dowex AG1-X8 column was from Bio-Rad Laboratories (Hercules PA, USA). Trichloroacetic acid (TCA) was purchased from Panreac (Barcelona, Spain). 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) was from Alexis Biochemicals (San Diego CA, USA), 9-tetrahydro-2-furyl)adenine (SQ-22536) was obtained from Calbiochem-Novabiochem Corporation (San Diego CA, USA). 12(S)-HETE levels were measured using an Ela kit according to the manufacturer’s instructions (Assay Designs, Ann Arbor MI, USA).

Platelet Aggregation Measurement

Platelets were acquired from the Blood Bank at the Galdakao Hospital in Spain. Platelet aggregation was carried out as described previously [25,26]. Briefly, washed human platelets were resuspended in HEPES buffer (10 mM HEPES pH 7.4, 145 mM NaCl, 5 mM KCl, 10 mM Glucose); apyrase free at 2.5 × 10⁹ cells/ml, aliquoted in 500 μl and placed in a siliconized glass cuvettes and prewarmed at 37°C without stirring. The samples were then placed into a thermostatted aggregometer at 37°C (Menarini model Aggregorder II PA-3220) and stirred before treatment. Aggregation was measured as the percentage of the maximum change in light transmission against a buffer blank for 10 min. All assays were performed in the presence of 1 mM CaCl₂.

[Ca²⁺]i Mobilization

[Ca²⁺]i levels were monitored and calculated as described [25,27]. Briefly, washed human platelets at 2.5 × 10⁹/ml in a nominally Ca²⁺-free standard medium (no added chelator or CaCl₂; pH 7.4) were loaded with 1 μM Fura-2 AM and 0.018 U/ml apyrase grade V at 37°C for 45 min. Subsequently, acid citrate dextrose was added (2% vol/vol; pH 6.5), and cells were washed by centrifugation (350 xg, 20 min, 20°C). Finally, cells were resuspended in fresh standard medium; apyrase-free at 2 × 10⁹ cells/ml. Cell aliquots (0.5 ml) were transferred to a cuvette and prewarmed at 37°C for 5 min.

Fluorescence was measured with a spectrophotometer (SLM Amino Bowman Series2, SLM) equipped with a thermostated cell holder and a magnetic stirrer. Fura-2 fluorescence was monitored continuously using monochromator settings of 340 and 380 nm (excitation) and 505 nm (emission). These experiments were performed either in the presence of 1 mM CaCl₂ or without external Ca²⁺ but with 2 mM EGTA-K₂-H₂O.

[3H]inositol Phosphates Generation

Measurement of [3H]inositol phosphates was carried out as described [25]. Briefly, washed human platelets were incubated with myo-[2-³H]inositol at 37°C for 3 hours. Subsequently, cells were washed and resuspended in HEPES buffer (pH 7.4) at 6–8 × 10⁹ cells/ml and then allowed to rest for ≥25 min before experimentation. Platelet suspensions (0.5 ml) were prewarmed at 37°C for 5 min followed by placing them into the aggregometer (37°C) and stirred. After stimulation, reaction was stopped by adding 0.5 ml ice-cold 10% (vol/vol) perchloric acid. Samples were centrifuged at 1,000 × g for 5 min at 4°C, and the supernatants were neutralized with 1.5 M KOH/75 mM HEPES and recentrifuged at 1,500 × g for 5 min at 4°C. The supernatant was diluted with 10 mM HEPES (pH 7.4)/2 mM EDTA. The [³H]inositol phosphates were separated by anion-exchange chromatography on a Dowex AG1-X8 column as described [25,26]. The radioactivity was measured in a liquid scintillation counter Tri-Carb (model 2700 TR Series; Packard Instrument Company, Meriden, CT).

cAMP Accumulation

Washed human platelets at 4 × 10⁹ cells/ml were aliquoted in 350 μl and placed into the aggregometer in a siliconized glass cuvettes warmed at 37°C and stirred before treatment. In order to prevent the rapid degradation of cAMP in a siliconized glass cuvettes warmed at 37°C and stirred before treatment. Aggregation was measured as the percentage of the maximum change in light transmission against a buffer blank for 10 min. All assays were performed in the presence of 1 mM CaCl₂.
increases of cAMP levels relative to the basal concentration measured on each experimental point.

**Measurement of the Levels of 12(S)-HETE by Immunoassay**

Washed human platelets at 1 x 10^9 cells/ml were aliquoted in 500 μl and placed before treatment into the aggregometer in a siliconized glass cuvettes warmed at 37°C and stirred. Cells were preincubated with 25 μM NDGA or vehicle for 5 min and subsequently were treated with 500 μM ATP or vehicle for 2 min at 37°C. Finally, cells were stimulated with 0.025 U/ml thrombin for 10 minutes at 37°C in the presence of 1 mM CaCl_2. After the stimulation, 2 volumes of methanol were added and the samples were stored at -20°C. To measure 12(S)-HETE, 50 μl supernatants of stimulated platelets were evaporated under a stream of N2, and the residue was resuspended with 250 μl of ice-cold phosphate buffer saline. 12(S)-HETE levels were measured using an EIA kit according to the manufacturer’s instructions (Assay Designs, Ann Arbor, MI).

**Statistical Analysis**

Results are expressed as means ± s.e.m. of the number of experiments indicated. Statistical significance between various conditions was assessed with Student’s t test.

**Results**

**ATP Inhibits Platelet Aggregation Mediated by Thrombin**

Washed human platelets were incubated with different concentrations of ATP (from 1 μM to 1 mM) for 2 min and were then stimulated with 0.025 U/ml thrombin for 2, 4, 6, 8 and 10 min. As shown in Figure 1A, ATP concentrations, higher than 10 μM inhibited both phases of platelet aggregation in response to thrombin, the primary response-rate of aggregation, and the final response-maximal aggregation. The presence of 1 mM Mg_2+ partially reversed the inhibition of TIPA mediated by ATP (Table 1). At higher concentrations Mg_2+ significantly inhibited by itself the extent of TIPA (data not shown). 1 mM Mg_2+ increased the IC_{50} for ATP from ~250 μM up to ~1 mM. These results suggested that ATP-mediated inhibition of platelet aggregation was ATP^4+ dependent. Additionally increasing the concentration of thrombin also shifted to the right the IC_{50} for ATP (1.2 mM and 4.6 mM at 0.05 U/ml and 0.5 U/ml thrombin, respectively) (Figure 1B).

Next, we investigated whether ATP-mediated inhibition of TIPA was time-dependent. Washed human platelets were incubated with different concentrations of ATP (100, 250, 500 μM) for 0, 2, 5, 10, 20, 30, 60 and 90 minutes and were then stimulated with 0.025 U/ml thrombin. At time 0 platelets were exposed simultaneously to both ATP and thrombin. In all time points maximal aggregation was measured 10 minutes after addition of thrombin including time 0. As shown in Figure 2 the inhibition of TIPA mediated by nucleotide was very fast at all ATP concentrations (15±5%, 41±5%, 73±13% at 100, 250 and 500 μM ATP, respectively). This inhibitory effect slightly increased with incubation time (maximum at 2 min for 100 μM ATP and 3 min for 250 and 500 μM ATP) followed by a strong decrease in the inhibition carried out by ATP mainly at 100 and 250 μM, respectively (Figure 2).

**Effects of Selective Antagonists of ADP Receptors, P2Y<sub>1</sub> and P2Y<sub>12</sub>, on the TIPA Inhibition Induced by ATP**

It is widely accepted that extracellular ATP is a competitive antagonist of ADP-induced platelet activation [19]. To examine the potential implication of ADP receptors in the ATP-mediated inhibition of TIPA, we studied the effect of A<sub>P2</sub>P, a selective antagonist for P2Y<sub>1</sub> receptor and 2-propylthio-b,γ-difluoromethylene-D-ATP (AR-C67085), a structural analogue of ATP and a selective antagonist for P2Y<sub>12</sub> receptor. Washed human platelets were preincubated or not with these compounds followed by incubation in the presence or absence of ATP and finally stimulated with 10 μM ADP. As shown in Figure 3 (A,B) ADP-induced platelet aggregation and this aggregation was strongly blocked by both P2Y selective antagonists (64% for 200 μM A<sub>P2</sub>P; n = 3, P<0.01 and 68% for 100 mM AR-C67085, n = 5, P<0.01) and by 50 μM ATP (79%, n = 5, P<0.001). The effect of ATP on this response was marginally increased by co-incubation with either A<sub>P2</sub>P or AR-C67085 (n = 5, P<0.05). Similar approach was developed to study the effects of these antagonists on the thrombin response. In this case, neither A<sub>P2</sub>P nor AR-C67085 significantly modified the platelet aggregation induced by thrombin (Figure 4 A,B). However, AR-C67085 slightly increased (23±10%) the inhibitory effect produced by 250 μM ATP (Figure 4B). Next, the combination of both compounds had a small inhibitory effect on the rate and extent of aggregation (6±1%) on thrombin-stimulated platelets (Figure 4C). While the pretreatment of platelets with both compounds slightly increased (14±5%) the inhibitory effect induced by 250 μM ATP (Figure 4C).

**Effect of ADA and Apyrase on the TIPA Inhibition Induced by ATP**

ATP effect on TIPA could be explained by the fast ATP hydrolysis to generate first AMP and subsequently adenosine, a well-known TIPA inhibitor. To test this possibility we examined the effect of ADA on our experimental system. As shown in Figure 5A, 1 U/ml ADA totally prevented TIPA inhibition induced by 10 μM adenosine (Fig. 5A, bars 2 and 6) in cells exposed to 0.025 U/ml thrombin. However, ADA was unable to modify the inhibitory effect of ATP on TIPA, both at 500 as 250 μM ATP (Fig. 5A, bars 3 and 7 and 4 and 8).

Further, to confirm that ATP itself was responsible for TIPA inhibition, we examined the effect of apyrase on platelet aggregation. Apyrase alone had no effect on TIPA (Figure 5B). Moreover, apyrase in the presence of ATP abolished the inhibitory effect induced by this nucleotide on platelet aggregation. The inhibition was reversed by 70% compared to platelets treated with thrombin and ATP in the absence of apyrase (Figure 5B). These results suggest that the presence of ATP in the incubation medium is required to observe the inhibitory effect on thrombin induced platelet aggregation.

**ATP Inhibits Second Messengers Generation Controlled by Thrombin**

Activation of platelets by thrombin involves phospholipase C (PLC) activation and is accompanied by an increase in [Ca^{2+}], mobilization and cation entry from the extracellular environment [5]. In order to decipher the mechanism by which ATP inhibited platelet aggregation, we studied the effect of ATP on thrombin-induced [Ca^{2+}], release in platelets. As shown in Figure 6A (upper panel), thrombin-induced robust intracellular calcium mobilization, from a baseline of 41 nM raise to 128 nM giving a maximum increase of 87±5 nM, however, this response was progressively...
and significantly inhibited by ATP in a dose dependent-manner. Maximal inhibition occurred in the presence of 3 mM ATP. Next, we studied the contribution of calcium from intracellular stores. To this end, the extracellular calcium was chelated with 2 mM EGTA. In these conditions thrombin induced a significant increase in intracellular calcium concentration (38±3 nM). This response was also blocked by ATP in a dose dependent-manner (Figure 6B, lower panel). Furthermore, ATP did not affect the basal [Ca2+]i neither in the presence nor in the absence of extracellular calcium. These results suggested that ATP interfered negatively with early signals controlled by thrombin in the platelet aggregation process.

A key element in early signalling is the PLC, which mediates inositol phosphate break-down to generate IP3, DAG and [Ca2+]i. In order to investigate whether ATP blocked PLC activation mediated by thrombin, we examined inositol phosphate generation in platelets. As shown in Figure 6B, ATP inhibited significantly in a dose dependent-manner inositol monophosphate (IP1), bisphosphate (IP2) and trisphosphate (IP3) generation induced by all thrombin concentrations tested (from 0.025 U/ml to 0.5 U/ml). Moreover, maximal concentration of ATP (3 mM) inhibited also basal levels of IP1, IP2, IP3 by 39, 17 and 11%, respectively. Taken together these results indicate that ATP blocks platelet aggregation induced by thrombin and this process should require PLC activation to induce inositol phosphate generation and calcium mobilization.

Effect of ATP on cAMP Generation in Human Platelets

In order to investigate the involvement of cyclic nucleotides and cyclic nucleotide-dependent protein kinases in the ATP-mediated inhibition of platelet responses, first we tested the guanylate cyclase inhibitor, ODQ which abolish the inhibitory effect of 10 μM SNP, (a nitric oxide donor that activates guanylate cyclase) on TIPA [26,30]. This compound did not prevent the platelet aggregation inhibition induced by 500 μM ATP suggesting that guanylate cyclase/cGMP pathway was not involved in this process (data not shown). Moreover, we tested an adenylate cyclase (AC) inhibitor, SQ-22536 even when this AC inhibitor did not modify the basal TIPA, this AC inhibitor was able to partially block the inhibition induced by ATP over TIPA (Figure 7D). Next, we studied the effect of ATP on the cAMP accumulation in human platelets. First, to avoid cAMP degradation, we performed these experiments in the presence of different phosphodiesterase inhibitors, as described in Materials and Methods. As shown in Figure 7A, ATP and its non-metabolizable analog, α,β-methylene ATP, increased cAMP levels in a time-dependent manner reaching the maximum cAMP concentration after 5 min (9±1, 11±1 and 7±1 pmol/10^9 cells for 500 μM ATP, 1 mM ATP and 500 μM α,β-methylene ATP respectively, n = 5, P<0.01). Longer incubations (up to 30 min) significantly reduced the increases in cAMP levels induced by 500 μM ATP (4±1 pmol/10^9 cells, n = 5, P<0.05) but did not affect the response to 1 mM ATP or α,β-methylene ATP (n = 5,

**Table 1. Effect of Mg^{2+} on ATP-mediated inhibition of TIPA.**

| [ATP] (mM) | − Mg^{2+} | + Mg^{2+} |
|-----------|-----------|-----------|
| 0         | 91±2      | 90±2      |
| 0.001     | 88±5      | 85±5      |
| 0.01      | 83±5      | 83±5      |
| 0.1       | 63±9      | 77±5      |
| 0.5       | 14±8      | 66±6      |
| 1         | 0±0       | 46±6      |
| 2         | 0±0       | 0±0       |

Washed human platelets were preincubated with different concentrations of ATP for 2 min in the absence (−Mg^{2+}) or in the presence (+Mg^{2+}) of 1 mM MgCl₂. Then, cells were stimulated with 0.025 U/ml thrombin. The aggregation was measured for 10 min. Values represent the average of maximal aggregation (% means±s.e.m) of 7 experiments with different platelet preparations. doi:10.1371/journal.pone.0067117.g001
P<0.05). Then, we examined whether cAMP accumulation could be detected in the absence of phosphodiesterase inhibitors. To do this, washed human platelets were treated with different concentrations of ATP for 5 minutes and cAMP levels were measured as described in Materials and Methods. As shown in the inset of Figure 7A, ATP induced an increase of intracellular cAMP levels in a dose-dependent manner. This increment was about 2 and 5 for 500 μM and 1 mM ATP respectively, whereas for the same concentrations of ATP in platelets which were pretreated with phosphodiesterase inhibitors the increments were about 9.5 and 11 (Figure 7A and inset). Nevertheless in the absence of inhibitors, the increment of cAMP was undetectable for 10 μM ATP and weakly detectable for 100 μM ATP, while at the same concentrations of ATP in the presence of phosphodiesterase inhibitors the increments were about 4.8 and 5.4 for 10 and 100 μM ATP respectively (Figure 7A inset compared to Figure 7C, first and second solid bars). Since, cAMP signal was amplified by using the cocktail of phosphodiesterase inhibitors, we decided to perform the other experiments related with the intracellular cAMP detection in the presence of phosphodiesterase inhibitors.

Next, we studied the effect of ATP on cAMP levels in thrombin-stimulated human platelets. Consistent with the results obtained by Kim et al. [31], we also found that 0.025 U/mL thrombin reduced basal cAMP levels in a time-dependent manner (~6±1 pmol/10^9 cells with respect to basal levels after 5 min, n = 5, P<0.01) (Figure 7B). However, when platelets were preincubated with 1 mM ATP for 2 minutes, followed by stimulation with thrombin (0, 2, 5 and 10 minutes), ATP not only blocked the effects of thrombin on the decreased of intracellular cAMP, but also ATP did the reverse effect, increasing cAMP to a value of 9 pmol/10^9 cells (Figure 7B). Nevertheless, thrombin did not modify the cAMP accumulation in response to different concentrations of ATP (Figure 7C). These results suggested that ATP inhibition over agonist-induced platelet aggregation required AC/cAMP pathway.

In a next set of experiments cAMP levels were measured in thrombin-stimulated platelets preincubated with AR-C67085 and treated or not with ATP. As shown in Figure 8, AR-C67085 increased cAMP levels in a dose-dependent manner, compared to control (platelet incubated with thrombin alone). Similar cAMP accumulation was observed in platelets incubated only in the presence of AR-C67085 (data not shown). When platelets were incubated first with different concentrations of AR-C67085 followed by 500 μM ATP, ATP also increased the cAMP intracellular levels in an AR-C67085 concentration independent manner. No potentiation or additive effect was observed by the combination of both P2Y12 receptor antagonists. Taken together these results suggested that ATP signalled through P2Y12 receptor in platelets to generate cAMP.

**NDGA Reverses the Platelet Aggregation Inhibition Mediated by ATP**

12-LO and its metabolites are involved in the control of platelet response [32]. Based on this, we investigated the potential implication of this enzyme on the TIPA inhibition exerted by ATP. We preincubated platelets with different concentrations of NDGA (a potent lipoygenases non-specific inhibitor) for 5 minutes, followed by 250 or 500 μM ATP and finally platelets were stimulated with thrombin. As shown in Figure 9A, the
inhibition of platelet aggregation mediated by ATP (45±3% and 74±5% respectively) was significantly reversed by NDGA at concentrations between 25 and 75 μM. Thereby in the presence of 25, 50 or 75 μM NDGA, the maximal inhibition was 23±7% (*P<0.05), 13±6% (**P<0.01) and 0±10% (**P<0.01), respectively. Resulting in a reversion of the inhibition induced by 250 μM ATP (50±10% (P<0.05), 73±13% (P<0.01) and 100±4% (P<0.01) at 25, 50 and 75 μM NDGA respectively, n = 4–9; Figure 9A). At 500 μM ATP and in the presence 25, 50 or 75 μM NDGA the reversion of inhibition was 60±12% (**P<0.01), 78±8% (**P<0.01) and 69±12% (*P<0.05) respectively (Figure 9A). We observed that 50 and 75 μM but not 25 μM NDGA inhibited the maximal platelet aggregation 10±1% and 26±3%, respectively (Figure 9A, solid squares), therefore we decided to use 25 μM NDGA in the next experiments.

To further confirm that concentrations of NDGA lower than 50 μM could significantly reverse the inhibition of TIPA mediated by ATP, we examined the effect of 25 μM NDGA on this process. As expected, 25 μM NDGA alone had no effect on TIPA aggregation.
Moreover, this concentration of inhibitor in the presence of ATP was able to reverse the aggregation blockade by 43% compared to platelets treated with thrombin and ATP in the absence of 25 μM NDGA (Figure 9B).

Next, we also examined the activity of 12-LO by measuring 12(S)-HETE generation. As shown in Figure 9C, thrombin stimulated 12(S)-HETE accumulation by more than 14-fold (second bar, hatched) over control (first bar, empty bar). The generation of 12(S)-HETE due to LO activity was blocked when platelets were preincubated with 25 μM NDGA followed by thrombin stimulation (Figure 9C, fourth bar, hatched), however, in the same experimental conditions, NDGA did not inhibit platelet aggregation induced by thrombin (Figure 9B). Regarding the ATP, this nucleotide (500 μM) inhibited the thrombin-response over platelet aggregation (Figure 9B) and also reversed totally 12(S)-HETE concentration to basal level (Figure 9C, third and sixth bars, solids). Nevertheless, we found that in non-thrombin stimulated cells, extracellular ATP does not affect basal levels of 12(S)-HETE (Figure 9C, first bar, empty). Taken together these results suggested that the signaling pathway related to LO and glutathione peroxidase is crucial on the inhibition of the aggregation performed by ATP, since when it is blocked, the nucleotide effect is reversed around 60% (Figure 9B).

However, it was not clear the role of 12(S)-HETE in this process. To clarify this point, we examined directly the effects of two arachidonic acid metabolites, 12(S)-HETE and 12(S)-HpETE on aggregation induced by thrombin in our experimental conditions. Platelets were incubated with different concentrations of those metabolites for 2 min followed by 0.025 U/ml Thrombin in the presence of 1 mM CaCl2, maximal aggregation was determined at 10 minutes. As shown in the inset of the Figure 9C, results indicated that neither 12(S)HpETE nor 12(S)-HETE were able to modify the platelet aggregation led by thrombin.

To investigate whether the effect of NDGA on ATP-mediated inhibition of TIPA was due to some interference in the cyclooxygenase route, we tested the effect of 15(S)-HETE, a specific inhibitor of platelet 12-LO without any effect on cycloxygenase [33]. 15(S)-HETE did not significantly affect platelet aggregation in response to thrombin. Nevertheless, as well as NDGA, 5 μM 15(S)-HETE reversed the ATP-mediated inhibition of TIPA (Figure 10A, 67±10% (n = 4, P<0.01).

Finally, we studied the effect of both NDGA and SQ-22536 on ATP-mediated inhibition of platelet aggregation. Results show...
that combined incubation with NDGA and SQ-22536 did not affect TIPA significantly (n = 6, P > 0.05; Figure 9D). However, ATP-mediated inhibition of TIPA was almost totally blocked. Inhibition of maximal aggregation by ATP alone was 76±5%, while it reached only 12±6% when both NDGA and SQ-22536 were present (Figure 10B).

Taken together these results suggested that ATP controlled intracellular anti-aggregation signals through 12(S)-LO pathway.

**Figure 5. Effect of ADA and apyrase on the ATP-mediated inhibition of TIPA.** (A) Washed human platelets were pretreated with 1 U/ml adenosine deaminase (+ ADA) or vehicle (- ADA) for 2 min. Cells were then incubated with 10 μM adenosine, 250 μM ATP, 500 μM ATP or vehicle (Control) for 2 min, and subsequently, stimulated with 0.025 U/ml thrombin (t, time = 0). Histogram represent the values of maximal aggregation (%), means ± s.e.m of 3 experiments with different platelet preparations. *P < 0.05, **P < 0.01. (B) Washed human platelets were pretreated with 500 μM ATP or vehicle for 2 min, and subsequently with 0.5 U/ml apyrase or vehicle for 1 min. Finally, platelets were stimulated with 0.025 U/ml thrombin. The aggregation was measured for 10 min and values represent the average curves of aggregation (%), means ± s.e.m of 3 experiments with different platelet preparations.

doi:10.1371/journal.pone.0067117.g005
In the present work we have shown that ATP was able to inhibit the aggregation of platelets in response to thrombin. The concentration of ATP in platelet granules is very high (between 100 and 400 mM) [34,35] and the degranulation of platelets transiently increases the concentration of ATP in a range between 50 and 100 mM [36,37]. Thus, the local concentration of ATP is probably much higher than the plasma concentration following platelet activation by thrombin [38]. Considering that the concentrations of ATP used in this work were very high, it could be argued that they would not correspond to physiological conditions, however, this assumption could be misleading, since it is recognized that the active form of ATP that regulates some P2X receptors activity is the free tetraionic form (ATP<sup>4-<sup>) [39,40].

The complexation of ATP by divalent and monovalent cations reduces significantly the concentration of the active form of ATP. The major decrease of ATP<sup>4-<sup> concentration occurs in the presence of Mg<sup>2+</sup> [40]. In a Mg<sup>2+</sup>-free medium containing 1 mM ATP and in the presence of Ca<sup>2+</sup>, Na<sup>+</sup> and K<sup>+</sup>, the concentrations of the active form of ATP are between 30 and 60 mM [40,41]. These effective concentrations correlate within the range of concentrations of ATP found after platelet degranulations [36,37].

Aggregation studies showed that the inhibition mediated by ATP was very rapid and dependent of this nucleotide, since pre-incubations with different concentrations of ADA (which completely block adenosine effects on platelet aggregation) had no effect on ATP-mediated inhibition of TIPA [42]. Platelets incubated with ATP beyond 15 minutes produced a decrease in the

---

**Figure 6. Effect of ATP on the thrombin-induced [Ca<sup>2+</sup>] mobilization and inositol phosphate generation.** (A) Fura 2-loaded human platelets were incubated for 2 min with different concentrations of ATP (from 0 to 3 mM) in the presence (upper panel) or in the absence of 1 mM CaCl<sub>2</sub> (lower panel). Then, cells were stimulated with 0.025 U/ml thrombin and the increase in [Ca<sup>2+</sup>], was measured for 90 s. The results are expressed as the variation of the [Ca<sup>2+</sup>] (Δ [Ca<sup>2+</sup>]), measured before the addition of thrombin (basal level) and after the addition of thrombin (the maximum increase in [Ca<sup>2+</sup>]). Histograms represent the means ± s.e.m of 5 experiments with different platelet preparations. In unstimulated cells the basal level in the presence of external calcium was 41 ± 1 nM and in the presence of EGTA was 30 ± 1 nM. In both cases, ATP did not affect the basal levels. **P<0.01, ***P<0.001. (B) [3H]Inositol-labeled platelets were incubated for 2 min with 0.5 (▲), 1 (●), 3 mM (▲) ATP or vehicle (■). Then, cells were stimulated with different concentrations of thrombin (0, 0.025, 0.05, 0.1 and 0.5 U/ml) in the presence of 1 mM CaCl<sub>2</sub>. The reaction was stopped 10 min after the stimulation. Data are the means ± s.d. of one experiment performed in triplicate and representative of 2 other experiments. Inositol monophosphate (upper panel, IP<sub>1</sub>), inositol bisphosphate (middle panel, IP<sub>2</sub>), and inositol trisphosphate (lower panel, IP<sub>3</sub>) were separated by anion-exchange chromatography on a Dowex AG1-X8 column. Error bars are omitted when they are smaller than symbol. *P<0.05, **P<0.01, ***P<0.001. doi:10.1371/journal.pone.0067117.g006

**Discussion**

In the present work we have shown that ATP were able to inhibit the aggregation of platelets in response to thrombin. The concentration of ATP in platelet granules is very high (between 100 and 400 mM) [34,35] and the degranulation of platelets transiently increases the concentration of ATP in a range between 50 and 100 μM [36,37]. Thus, the local concentration of ATP is probably much higher than the plasma concentration following platelet activation by thrombin [38]. Considering that the concentrations of ATP used in this work were very high, it could be argued that they would not correspond to physiological conditions, however, this assumption could be misleading, since it is recognized that the active form of ATP that regulates some P2X receptors activity is the free tetraionic form (ATP<sup>4-</sup>) [39,40].
inhibition of the platelet aggregation. This reduction could be due either to a slow desensitization of the putative purinergic receptor involved in the response or to the action of ectonucleotidases or more likely of ectoapyrases bound to the platelet membrane in humans and rodents [42,43]. In fact, the presence of apyrase in our experimental conditions corroborated that the observed inhibition on platelet aggregation was ATP dependent.

Besides aggregation, we found that ATP also inhibited the increase of the [Ca^{2+}], induced by thrombin being this inhibition independent of the extracellular calcium, moreover, ATP also inhibited phosphatidyl inositol break-down at all concentrations of thrombin tested. These results suggest that PLC activity is affected by ATP. In agreement with that, Soslau et al. reported that extracellular ATP inhibited the calcium mobilization from intracellular pools by various agonists like collagen, thrombin or an analogue to thromboxane A_2 [44,45]. Similarly, we have described a mechanism independent of calcium influx, in which calcium increases induced by carbachol can be blunted by the activation of a P2X receptor with low affinity for ATP [46]. However, this inhibitory effect of ATP on intracellular calcium increases is controversial, it has also been reported that the ATP released from activated platelets induces intracellular calcium increases through P2X_1 receptors [47–49]. These contrary results are probably due to differences in the experimental procedures. In order to prevent P2X_1-receptor desensitization, platelet preparations were treated with apyrase [47–49]. While in our conditions

**Figure 7. Effect of ATP on the cAMP levels in human platelets.** (A) Washed human platelets were preincubated with a mixture of phosphodiesterase inhibitors for 5 min at 37°C, as indicated in Materials and Methods. Then, cells were incubated with 500 μM (●) or 1 mM (▲) ATP, ( ■) 500 μM αβ-methylene ATP or vehicle for 2, 5, 10, 20 and 30 min. Inset, Washed human platelets were incubated with different concentrations of ATP for 5 min at 37°C in the absence of phosphodiesterase inhibitors. The reactions were stopped by addition of ice-cold TCA (10% final concentration). The cAMP levels were determined as described in Materials and Methods. Data represent the means ± s.e.m of 5 experiments with different platelets preparations, performed in duplicate and assayed in triplicate. (B) Washed human platelets were preincubated with a mixture of phosphodiesterase inhibitors for 5 min at 37°C, as indicated in Materials and Methods. Then, cells were incubated with or without 1 mM ATP for 5 min at 37°C. Finally, cells were stimulated with 0.025 U/ml for 0, 2, 5 and 10 min in the presence of 1 mM CaCl_2. The reaction was stopped by addition of ice-cold TCA (10% final concentration). The cAMP levels were determined as described in Materials and Methods. Data are the means ± s.e.m of 5 experiments with different platelets preparations, performed in duplicate and assayed in triplicate. (C) Washed human platelets were also preincubated with a mixture of phosphodiesterase inhibitors for 5 min followed by incubation in the presence of various concentrations of ATP or vehicle for 5 min and finally stimulated with 0.025 U/ml thrombin or vehicle for 5 min in the presence of 1 mM CaCl_2. The reaction was stopped by addition of ice-cold TCA (10% final concentration). The cAMP levels were determined as described in Materials and Methods. Data are the means ± s.e.m of 5 experiments with different platelets preparations, performed in duplicate and assayed in triplicate. *P<0.05, **P<0.01, ***P<0.001. (D) Washed human platelets were preincubated with 200 μM SQ-22536 or vehicle for 2 min. Then, cells were incubated with 500 μM ATP or vehicle for additionally 2 min. Finally, cells were stimulated with 0.025 U/ml thrombin (●, time = 0). The aggregation was measured for 10 min and values represent the average curves of aggregation (%), mean±s.e.m of 4 experiments with different platelet preparations.

doi:10.1371/journal.pone.0067117.g007
apyrase was not used, this absence pointed out that P2X1 receptor would not be involved in this early signalling due to this receptor desensitizes in milliseconds without the presence of apyrase [20,48,50–52].

Many compounds exert their inhibition on TIPA through an increase in basal levels of cyclic nucleotides such as prostaglandins and NO donors [26,53,54]. ATP and α,β-methylene ATP produced a dose- and time-dependent increase in cAMP concentration. The increase in cAMP was rapid and transient, especially in the presence of ATP. This kinetic was probably due to the decrease of ATP concentration by ATP-specific ecto-apyrases. ODQ, a guanylate-cyclase inhibitor, did not alter the effect of ATP, suggesting that the increase in cAMP was not the result of the inhibition of the cyclic nucleotide phosphodiesterase type 3 by cGMP [53]. SQ-22536, an AC inhibitor, partially blocked the inhibition exerted by ATP on TIPA. According with that, Soslau et al. using 2′,5′-dideoxyadenosine as an AC inhibitor, reported that this compound partially reversed ATP-mediated inhibition of collagen-induced aggregation [55].

The levels of cAMP in platelets play a key role in the control of the activation/aggregation by thrombin. Eigenthaler et al. estimated that intracellular cAMP concentration in unstimulated washed platelets was 4.4 μM, similar to the concentration of cAMP binding sites of PKA [56]. Slight increases or decreases in these cAMP levels are sufficient to regulate in a positive or negative manner the activity of PKA and consequently the platelets are relaxed or activated [53,57].

Thrombin reduces cAMP concentrations below the basal levels through the ADP secreted from dense granules in thrombin activated platelets [16,31,45]. ATP had the opposite effect, increasing cAMP levels independently of the presence of thrombin. When platelets were incubated at the same time with ATP and AR-C67085, a specific antagonist of P2Y12 receptors, AR-C67085 also increased in a dose-dependent manner the cAMP levels with a maximum increase at 10 μM. No potentiation or additive effect was observed when AR-C67085 was added to a maximal concentration of ATP, suggesting that ATP was acting on P2Y12 receptors with low affinity [58].

It has been reported that ADP contributes to platelet aggregation in response to low concentrations of thrombin [58]. However, we observed that apyrase did not significantly modify maximum aggregation induced by 0.025 U/ml thrombin. This is consistent with the results obtained by Ishii-Watabe et al. who reported that apyrase did not affect aggregation induced by 0.1 U/ml thrombin but fully inhibited the plasmin-induced aggregation [59]. The pharmacological inhibition of P2Y1 receptors with the antagonist A3P5P or N6-methyl-2′,5′-dideoxyadenosine-3′,5′-bisphosphate (MRS2179) had no effect on TIPA and it had no additional effects in combination with AR-C69931, an antagonist of P2Y12 [16]. These results confirmed those obtained from P2Y1 receptor-null mice, in which the absence of expression of these receptors did not affect TIPA [60]. The blockade of P2Y12 receptors with AR-C67085 did not inhibit thrombin-induced irreversible platelet aggregation; it slightly inhibited both phases of platelet aggregation, the primary response-rate of aggregation and the final response-maximal aggregation in response to 0.025 U/ml thrombin. Inhibition of maximal aggregation was reached at 1 μM, the contribution of this receptor to platelet aggregation was estimated about ~12% in our conditions. Similar results were obtained in studies made on whole blood aggregation [16].

**Figure 8. Effect of AR-C67085 concentrations on the cAMP levels in thrombin stimulated human platelets.** Washed human platelets were preincubated with a mixture of phosphodiesterase inhibitors for 5 min. Then, cells were incubated in the presence of various concentrations of AR-C67085 (0.1, 1, 10 μM) or vehicle for 10 min and subsequently, were incubated in the presence of ATP (500 μM) or vehicle for 2 min. Finally, cells were stimulated with 0.025 U/ml thrombin for 5 min in the presence of 1 mM CaCl2. The reaction was stopped by the addition of ice-cold TCA (10% final concentration). The cAMP levels were determined as described in Experimental Procedures. Data are the means ± s.e.m of 4 experiments with different platelets preparations, performed in duplicate and assayed in triplicate. The increases in cAMP levels with respect to basal levels (Δ[cAMP], pmol/10⁹ platelets) are indicated. *P<0.5, **P<0.01 when compared to platelets not incubated with AR-C67085 in the absence of ATP and #P>0.05 in the presence of ATP, respectively.

doi:10.1371/journal.pone.0067117.g008
results reveal that the inhibition of TIPA by ATP just cannot be explained by competitive inhibition at ADP receptor levels. In summary, we found that ATP increased cAMP levels by regulating negatively the P2Y12 receptor activation mediated by ADP and inhibiting platelet activation/aggregation induced by thrombin. Extracellular nucleotides such as ATP, GTP and AMP are involved in the activation of cyclooxygenase and 12-LO in washed human platelets [24]. The arachidonic acid released by phospholipase A2 is a substrate of 12-LO for the production of 12(S)-HETE in platelets [61]. We have observed that ATP by itself did not affect phospholipase A2 activity (not shown), furthermore thrombin increases the 12(S)-HETE levels [62]. This eicosatetraenoic acid derivative modulates the platelet activity and pathological thrombus in acute coronary syndromes [63]. Regarding to platelet aggregation, it has been found that 12(S)-HETE enhances this process mediated by agonists such as thrombin by decreasing cAMP levels [63–65]. However, the inhibition of the 12-LO activity by either NDGA or 15(S)-HETE, a more specific 12-LO inhibitor, did not affect TIPA. Similar data have been obtained in platelets from 12-LO knock-out mice [66]. ATP decreased 12(S)-HETE levels in thrombin-stimulated human platelets, and its inhibition on TIPA was reversed by blocking 12-LO. These results suggest that a metabolite of the AA/12-LO pathway mediated the inhibition of TIPA by ATP. Based on preliminary results showing that ATP does not modify thrombin stimulated 12(S)-HpETE formation (not shown), we hypothesize that a derivative of 12(S)-HpETE different to 12(S)-HETE could be responsible for the antiaggregant effect produced by ATP. In fact, there is evidence supporting the role of these metabolites as inhibitors of platelet aggregation induced by different agonists [67].

When both AC and 12-LO were simultaneously inactivated by SQ-22536 and NDGA respectively, ATP-mediated TIPA inhibi-
tion was almost completely abolished. This effect was additive not synergistic, suggesting the presence of two different and independent mechanisms whereby ATP exerted its inhibition. According to this, platelet incubated either with NDGA or 15(S)-HETE did not lead to any significant change in cAMP levels (data not shown), indicating that 12-LO inhibition did not interfere with the effect of ATP on AC. Conversely the inhibition of AC with SQ-22536 did not affect thrombin stimulated 12(S)-HETE formation or ATP-mediated inhibition of this hydroxylipid (data not shown).

In conclusion, we have shown that the inhibition of either AC or 12-LO pathway reverses ATP-mediated inhibition of TIPA. Furthermore, ATP exerts its inhibitory effect over TIPA at least through two different and independent signalling routes: 1) by regulating AC activity; the intracellular cAMP levels negatively affects the intracellular signalling controlled by thrombin, and also interferes with the ADP/P2Y12-receptor pathways led by thrombin. In addition, we postulate that the rapid effect of ATP on TIPA inhibition could also be originated by a direct allosteric interaction between the ATP and a P2 receptor different to P2Y12. Although the molecular mechanism remains to be elucidated; 2) through another unknown molecular mechanism that involves to the 12-LO pathway. Future studies will focus on the P2 receptor identification as well as the characterization of the molecular

Figure 10. Effect of NDGA on the ATP-mediated inhibition of platelet aggregation. Washed human platelets were preincubated with (A) 5 μM 15(S)-HETE or vehicle for 2 min. Then cells were incubated in the presence of 500 μM ATP or vehicle for 2 min. Finally, cells were stimulated with 0.025 U/ml thrombin (t, time = 0). The aggregation was measured for 10 min. Values represent the extent of aggregation at 10 minutes (%; means±s.e.m) of 4 experiments with different platelet preparations. (B) cells were preincubated with 25 μM NDGA or vehicle for 5 min and with 200 μM SQ-22536 or vehicle for 2 min. Then, cells were incubated in the presence of 500 μM ATP or vehicle for 2 min. Finally, cells were stimulated with 0.025 U/ml thrombin (t, time = 0). The aggregation was measured for 10 min. Values represent the extent of aggregation at 10 minutes (%; means±s.e.m) of 6 experiments with different platelet preparations.

doi:10.1371/journal.pone.0067117.g010
event leading to the cooperation between cAMP and 12-LO pathways to inhibit the platelet aggregation induced by thrombin.

Acknowledgements

We thank Drs. I. Zuazua and A. Ibarra Fontan for platelet preparations. Dr. N. Suarez Gonzalez and Dr. J.M. Bocynarres (Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles) for the generous gift of AR-C67085 compound and Dr M. Garcia Marcos (Department of Biochemistry, Boston University, School of Medicine) for helpful comments on the manuscript.

Author Contributions

Conceived and designed the experiments: AM. Performed the experiments: JB MC. Analyzed the data: JB MC LAP JLZ JPD AM. Contributed reagents/materials/analysis tools: JB MC LAP JLZ JPD AM. Wrote the paper: JLZ AM.

References

1. Shankar H, Kahlner B, Kunnapu SP (2006) G-protein dependent platelet signaling-perspectives for therapy. Curr Drug Targets 7: 1253–1263.
2. Zhou L, Schmaier AH (2005) Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am J Clin Pathol 125: 172–183.
3. Lechtenberg BC, Freund SM, Huntington JA (2009) An ensemble view of thrombin allosterity. Biol Chem 390: 899–896.
4. Coughlin SR (2005) Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3: 1800–1814.
5. Staller TJ, Newman DK, Ma P, Wannemacher KM, Brass LF (2012) Platelet signaling. Handb Exp Pharmacol. 59–65.
6. Hechler B, Gachet C (2011) P2 receptors and platelet function. Purinergic Signal 7: 921–953.
7. Garcia AE, Mada SR, Rico MC, Dela Cadena RA, Kunapuli SP (2011) ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to extracellular ATP. J Thromb Haemost 9: 387–392.
8. Cosemans JM, Munnix IC, Wetzker R, Keller R, Jackson SP, et al. (2006) Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood 108: 3045–3052.
9. Schoenwaelder S, Ono A, Sturgeon S, Chan SM, Mangin P, et al. (2007) ATP inhibits platelet aggregation, Ca2+ influx, and nitric oxide generation in intact platelets: Evidence for an inhibitory PI3K activity. J Biol Chem 282: 20681–20685.
10. Dragan YP, Ellis EF (1990) Effect of adenine nucleotides on cyclooxygenase and lipooxygenase enzyme products of arachidonic acid in human platelets. Biochem Pharmacol 39: 27–32.
11. Hechler B, Mada SR, Rico MC, Dela Cadena RA, Kunapuli SP (2011) ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to extracellular ATP. J Thromb Haemost 9: 387–392.
12. Shankar H, Kahner B, Kunapuli SP (2006) G-protein dependent platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am J Clin Pathol 125: 172–183.
13. Grandi K, Aktories K, Jakobs KH (1986) Evidence for two GTPases activated by thrombin in membranes of human platelets. Thromb Haemost 57: 1180–1187.
14. Lechtenberg BC, Freund SM, Huntington JA (2009) An ensemble view of thrombin allosterity. Biol Chem 390: 899–896.
15. Adam F, BVerbeuren T, Fauchere J, Guillin M, Jandrot-Perrus M (2003) Activation by P2X7 agonists of two phospholipases A2 (PLA2) in ductal cells of rat submandibular gland. Coupling of the calcium-independent PLA2 with activation by extracellular ATP in rat parotid acinar cells. Biochimica et Biophysica Acta 1268: 73–80.
16. Chambers DA, Salzman EW, Neri LL (1967) Characterization of ‘‘ecto-ATPase’’ activity in membranes of human platelets. Biochem J 103: 467–475.
17. Marcondes S, Cardoso MH, Morganti RP, Thomazzi SM, Lilla S, et al. (2006) Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood 108: 3045–3052.
18. Hechler B, Gachet C (2011) P2 receptors and platelet function. Purinergic Signal 7: 921–953.
19. Cosemans JM, Munnix IC, Wetzker R, Keller R, Jackson SP, et al. (2006) Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood 108: 3045–3052.
20. Dragan YP, Ellis EF (1990) Effect of adenine nucleotides on cyclooxygenase and lipooxygenase enzyme products of arachidonic acid in human platelets. Biochem Pharmacol 39: 27–32.
21. Mahaut-Smith MP, Tolhurst G, Evans RJ (2004) Emerging roles for P2X1 pathways to inhibit the platelet aggregation induced by thrombin. J Thromb Haemost 2: 243–249.
22. Hechler B, Mada SR, Rico MC, Dela Cadena RA, Kunapuli SP (2011) ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to extracellular ATP. J Thromb Haemost 9: 387–392.
23. Kim S, Foster G, Lecchi A, Quinton TM, Prosser DM, et al. (2002) Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood 99: 3629–3636.
24. Gordon JL, van Stull F, Magnenat S, Zighetti ML, Kassack MU, et al. (2005) ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to extracellular ATP. J Thromb Haemost 3: 1800–1814.
aspirin-treated platelets by thrombin and epinephrine. J Biol Chem 283: 18493–18504.

48. Erhardt JA, Toomey JR, Douglas SA, Johns DG (2006) P2X1 stimulation promotes thrombin receptor-mediated platelet aggregation. J Thromb Haemost 4: 882–889.

49. Fung CY, Cendana C, Farndale RW, Mahaut-Smith MP (2007) Primary and secondary agonists can use P2X(1) receptors as a major pathway to increase intracellular Ca(2+) in the human platelet. J Thromb Haemost 5: 910–917.

50. Rolf MG, Becarly CA, Mahaut-Smith MP (2001) Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP. Thromb Haemost 85: 303–308.

51. North RA, Jarvis MF (2012) P2X Receptors as Drug Targets. Mol Pharmacol 83: 759–769.

52. Cauwenberghs S, Feijge MA, Hageman G, Hoylaerts M, Akkerman JW, et al. (2006) Plasma ectonucleotidases prevent desensitization of purinergic receptors in stored platelets: importance for platelet activity during thrombus formation. Transfusion 46: 1018–1028.

53. Maurice DH, Haslam RJ (1990) Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 37: 671–681.

54. Smolenaski A (2012) Novel roles of cAMP/cGMP-dependent signaling in platelets. J Thromb Haemost 10: 167–176.

55. Soslow G, Brodsky I, Parker J (1993) Occupancy of P2 purinoceptors with unique properties modulates the function of human platelets. Biochem Biophys Acta 1177: 199–207.

56. Eigenbrot M, Nolte C, Halberse M, Walter U (1992) Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. Eur J Biochem 205: 471–481.

57. Seiler S, Gillesepi E, Arnold AJ, Brassaed CL, Meanwell NA, et al. (1991) Imidazolquoline derivatives: potent inhibitors of platelet cAMP phosphodiesterase which elevate cAMP levels and activate protein kinase in platelets. Thromb Res 62: 31–42.

58. Gachet C (2003) The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther 108: 180–192.

59. Ishii-Watabe A, Uchida E, Mizuguchi H, Hayakawa T (2000) On the mechanism of plasmin-induced platelet aggregation. Implications of the dual role of granule ADP. Biochem Pharmacol 59: 1345–1355.

60. Leon G, Hecher B, Freund M, Eckel A, Vial C, et al. (1999) Defective platelet aggregation and increased resistance to thrombolysis in purinergic P2Y(1) receptor-null mice. J Clin Invest 104: 1737–1739.

61. Rietdouw D, Grav J, Wyeck PK, Lahibert F, Vergy J, et al. (1994) Arachidonyl trihydroxymethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. J Biol Chem 269: 15619–15624.

62. Gonzalez-Nunez D, Claria J, Rivera F, Poch E (2001) Increased levels of 12(S)-HETE in patients with essential hypertension. Hypertension 37: 334–338.

63. Kaur G, Jalagadhigula G, Mao G, Rao AK (2010) RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. Blood 115: 3128–3135.

64. Samuelsson B (2012) Role of basic science in the development of new medicines: examples from the eicosanoid field. J Biol Chem 267: 10070–10080.

65. Zoccarato F, Ruzzene M, Cavallini L, Dossi MG, Francesconi MA, et al. (1991) Platelet responses promoted by the activation of protein kinase C or the increase of cytosolic Ca2+ are potentiated by adrenaline. Effects of cAMP and staurosporine. Biochem Biophys Acta 1092: 72–78.

66. Johnson EN, Brice LF, Funk CD (1996) Increased platelet sensitivity to ADP in mice lacking platelet-type 12-lipoxygenase. Proc Natl Acad Sci U S A 93: 3100–3105.

67. Nijag S, Zafirou MP (2005) Heparin A3 synthase. Biochem Biophys Res Commun 330: 161–168.